BACKGROUND:Remission rates of 76, 69.5 and 64.3% have been reported in patients with nontumoural hyperprolactinaemia (NTH), microprolactinoma and macroprolactinoma, respectively, 2-5 years after cabergoline (CAB) withdrawal. OBJECTIVE: To report the estimated recurrence rate at 24-96 months after CAB withdrawal and indicate predictors of disease remission. DESIGN: Observational, analytical, prospective. PATIENTS: Of 381 previously untreated de novo patients with hyperprolactinaemia, 221 (58%) (173 women, 48 men; 27 with NTH, 115 with micro-, and 79 with macroprolactinoma) were studied. MEASUREMENTS: Using multiple regression analysis the diagnostic accuracy of nadir PRL levels (t = 7.6, P < 0.0001) and nadir maximal tumour diameter at CAB withdrawal (t = 3.9, P < 0.001) was analysed using receiver operating characteristic (ROC) curves. RESULTS: The recurrence of hyperprolactinaemia was 25.9, 33.9 and 53.1% in patients with NTH, micro- or macroprolactinoma, respectively. To predict the last PRL level after withdrawal, the optimum cut-off of nadir PRL levels at withdrawal was 162 mU/l (5.4 microg/l) [sensitivity (95% CI) 76% (67-84%), specificity 65% (51-77%)] and that of nadir maximal tumour diameter was 3.1 mm [sensitivity 52% (41-63%), specificity 86% (79-91%)]. The patients achieving both nadir PRL levels </= 162 mU/l and maximal tumour diameter </= 3.1 mm (n = 111) at CAB withdrawal had a significantly lower Kaplan-Meier estimate of recurrence of hyperprolactinaemia (20%) at 24-96 months than those who did not fulfil any of these criteria [(n = 38) 90%; P < 0.0001]. Patients achieving nadir PRL levels </= 162 mU/l (n = 26) or maximal tumour diameter </= 3.1 mm during CAB treatment (n = 46) had an estimated recurrence rate of hyperprolactinaemia of 50 and 56%, respectively. CONCLUSION: Persistent remission of hyperprolactinaemia without any evidence of tumour re-growth after 24-96 months of CAB withdrawal occurred in the majority of patients with NTH and microprolactinoma and in about half of those with macroprolactinoma. Nadir PRL levels and maximal tumour diameter at CAB withdrawal of </= 162 mU/l and </= 3.1 mm predicted remission of hyperprolactinaemia in 80% of patients.

Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy / Colao, Annamaria; Di Sarno, A; Guerra, Ermelinda; Pivonello, Rosario; Cappabianca, Paolo; Caranci, Ferdinando; Elefante, Andrea; Cavallo, LUIGI MARIA; Briganti, Francesco; Cirillo, S; Lombardi, Gaetano. - In: CLINICAL ENDOCRINOLOGY. - ISSN 0300-0664. - STAMPA. - 67:3(2007), pp. 426-433. [10.1111/j.1365-2265.2007.02905.x]

Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy.

COLAO, ANNAMARIA;GUERRA, ERMELINDA;PIVONELLO, ROSARIO;CAPPABIANCA, PAOLO;CARANCI, FERDINANDO;ELEFANTE, ANDREA;CAVALLO, LUIGI MARIA;BRIGANTI, FRANCESCO;LOMBARDI, GAETANO
2007

Abstract

BACKGROUND:Remission rates of 76, 69.5 and 64.3% have been reported in patients with nontumoural hyperprolactinaemia (NTH), microprolactinoma and macroprolactinoma, respectively, 2-5 years after cabergoline (CAB) withdrawal. OBJECTIVE: To report the estimated recurrence rate at 24-96 months after CAB withdrawal and indicate predictors of disease remission. DESIGN: Observational, analytical, prospective. PATIENTS: Of 381 previously untreated de novo patients with hyperprolactinaemia, 221 (58%) (173 women, 48 men; 27 with NTH, 115 with micro-, and 79 with macroprolactinoma) were studied. MEASUREMENTS: Using multiple regression analysis the diagnostic accuracy of nadir PRL levels (t = 7.6, P < 0.0001) and nadir maximal tumour diameter at CAB withdrawal (t = 3.9, P < 0.001) was analysed using receiver operating characteristic (ROC) curves. RESULTS: The recurrence of hyperprolactinaemia was 25.9, 33.9 and 53.1% in patients with NTH, micro- or macroprolactinoma, respectively. To predict the last PRL level after withdrawal, the optimum cut-off of nadir PRL levels at withdrawal was 162 mU/l (5.4 microg/l) [sensitivity (95% CI) 76% (67-84%), specificity 65% (51-77%)] and that of nadir maximal tumour diameter was 3.1 mm [sensitivity 52% (41-63%), specificity 86% (79-91%)]. The patients achieving both nadir PRL levels
2007
Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy / Colao, Annamaria; Di Sarno, A; Guerra, Ermelinda; Pivonello, Rosario; Cappabianca, Paolo; Caranci, Ferdinando; Elefante, Andrea; Cavallo, LUIGI MARIA; Briganti, Francesco; Cirillo, S; Lombardi, Gaetano. - In: CLINICAL ENDOCRINOLOGY. - ISSN 0300-0664. - STAMPA. - 67:3(2007), pp. 426-433. [10.1111/j.1365-2265.2007.02905.x]
File in questo prodotto:
File Dimensione Formato  
predictor of tumor.pdf

solo utenti autorizzati

Tipologia: Documento in Post-print
Licenza: Accesso privato/ristretto
Dimensione 163.26 kB
Formato Adobe PDF
163.26 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/418546
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 95
  • ???jsp.display-item.citation.isi??? 78
social impact